» Articles » PMID: 20019167

New Insights into Epithelial-mesenchymal Transition in Kidney Fibrosis

Overview
Specialty Nephrology
Date 2009 Dec 19
PMID 20019167
Citations 382
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial-mesenchymal transition (EMT), a process by which differentiated epithelial cells undergo a phenotypic conversion that gives rise to the matrix-producing fibroblasts and myofibroblasts, is increasingly recognized as an integral part of tissue fibrogenesis after injury. However, the degree to which this process contributes to kidney fibrosis remains a matter of intense debate and is likely to be context-dependent. EMT is often preceded by and closely associated with chronic interstitial inflammation and could be an adaptive response of epithelial cells to a hostile or changing microenvironment. In addition to tubular epithelial cells, recent studies indicate that endothelial cells and glomerular podocytes may also undergo transition after injury. Phenotypic alteration of podocytes sets them in motion to functional impairment, resulting in proteinuria and glomerulosclerosis. Several intracellular signal transduction pathways such as TGFbeta/Smad, integrin-linked kinase (ILK) and Wnt/beta-catenin signaling are essential in controlling the process of EMT and presently are potential targets of antifibrotic therapy. This review highlights the current understanding of EMT and its underlying mechanisms to stimulate further discussion on its role, not only in the pathogenesis of renal interstitial fibrosis but also in the onset of podocyte dysfunction, proteinuria, and glomerulosclerosis.

Citing Articles

Recent advances in understanding the mechanisms by which sodium-glucose co-transporter type 2 inhibitors protect podocytes in diabetic nephropathy.

Chen X, Wang M, Yan Z Diabetol Metab Syndr. 2025; 17(1):84.

PMID: 40051002 PMC: 11887226. DOI: 10.1186/s13098-025-01655-2.


Salivary proteomics profiling reveals potential biomarkers for chronic kidney disease: a pilot study.

Picolo B, Silva N, Martins M, Almeida-Souza H, de Sousa L, Polveiro R Front Med (Lausanne). 2025; 11:1302637.

PMID: 39895822 PMC: 11784343. DOI: 10.3389/fmed.2024.1302637.


METTL10 attenuates adriamycin-induced podocyte injury by targeting cell dedifferentiation.

Bao J, Li Z, Yao H, Wu B, Gu L, Pan Y Sci Rep. 2025; 15(1):1218.

PMID: 39774961 PMC: 11707283. DOI: 10.1038/s41598-024-80526-8.


5-Methoxytryptophan Protects against Toll-Like Receptor 2-Mediated Renal Tissue Inflammation and Fibrosis in a Murine Unilateral Ureteral Obstruction Model.

Wu J, Lee G, Chueh Y, Kuo C, Hsu Y, Wu K J Innate Immun. 2025; 17(1):78-94.

PMID: 39773569 PMC: 11801855. DOI: 10.1159/000543275.


Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies.

Di X, Li Y, Wei J, Li T, Liao B Adv Sci (Weinh). 2024; 12(3):e2410416.

PMID: 39665319 PMC: 11744640. DOI: 10.1002/advs.202410416.


References
1.
Sato M, Muragaki Y, Saika S, Roberts A, Ooshima A . Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest. 2003; 112(10):1486-94. PMC: 259132. DOI: 10.1172/JCI19270. View

2.
Yamaguchi Y, Iwano M, Suzuki D, Nakatani K, Kimura K, Harada K . Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis. 2009; 54(4):653-64. DOI: 10.1053/j.ajkd.2009.05.009. View

3.
Burns W, Kantharidis P, Thomas M . The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs. 2007; 185(1-3):222-31. DOI: 10.1159/000101323. View

4.
Zeng R, Yao Y, Han M, Zhao X, Liu X, Wei J . Biliverdin reductase mediates hypoxia-induced EMT via PI3-kinase and Akt. J Am Soc Nephrol. 2008; 19(2):380-7. PMC: 2396754. DOI: 10.1681/ASN.2006111194. View

5.
Wiggins J, Goyal M, Sanden S, Wharram B, Shedden K, Misek D . Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol. 2005; 16(10):2953-66. DOI: 10.1681/ASN.2005050488. View